Safety analysis of high‐dose methotrexate in pediatric non‐Hodgkin lymphomas

alexandrossfakianakis shared this article with you from Inoreader Safety analysis of high‐dose methotrexate in pediatric non‐Hodgkin lymphomas via Pediatric Blood & Cancer Abstract High-dose methotrexate (HD-MTX) with rigorous supportive care is essential to the treatment of pediatric non-Hodgkin lymphomas (NHL). We describe the safety and tolerability of HD-MTX in patients with NHL treated at our center. In our cohort of 46 patients, the majority had at least one course of delayed clearance and/or creatinine elevation. Additionally, more than one-third of patients experienced an episode of grade ≥3 mucositis. Creatinine elevations and delayed clearance were independently associated with subsequent grade ≥3 mucositis. We advocate for greater availability of methotrexate monitoring to allow dose escalation of this essential modality around the world. View on Web

Inoreader. Take back control of your news feed. Follow us on Twitter and Facebook.